| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Liu,Li-Cheng | Chairman | 0.83% | |
| Cheng,Zheng-Yu | Director | 6.06% | Formosa Laboratories, Inc. |
| Chen,Tou-Hui | Director | 4.99% | EXECUTIVE YUAN NATIONAL DEVELOPMENT FUND MANAGEMENT COUNCIL |
| MANAGEMENT COMMITTEE OF YAOHUA GLASS CO., LTD. | Director | 4.27% | |
| Lv,Jun-Fu | Director | 8.98% | FOXCONN TECHNOLOGY CO., LTD. |
| Chen,Yu-Ting | Director | 8.98% | FOXCONN TECHNOLOGY CO., LTD. |
| Chen,Bo-Zhi | Independent Director | 0.00% | |
| Chen,Ming-Xian | Independent Director | 0.00% | |
| Yin,Fu-Xiu | Independent Director | 0.00% | |
| Zhang,Ming-Chao | Independent Director | 0.00% |
Change Person in Charge to Liu,Li-Cheng
2022/07/06
Change Capital to 4,000,000,000
2021/08/27
Change Capital to 3,000,000,000
2019/12/06
Change Capital to 2,000,000,000
2018/04/20
Change Capital to 1,200,000,000
2015/01/30
Change Person in Charge to Li,Zhong-He
2013/10/21
Change Capital to 540,000,000
2013/06/17
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 181,923 | 1,008,960 | 1,022,653 |
| Operating cost | 164,763 | 789,975 | 785,912 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 17,160 | 218,985 | 236,741 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 17,160 | 218,985 | 236,741 |
| Operating expenses | 239,980 | 1,172,786 | 1,268,718 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -222,820 | -953,801 | -1,031,977 |
| Non-operating income and expenses | 66,083 | 257,296 | 118,327 |
| Net profit (loss) before tax | -156,737 | -696,505 | -913,650 |
| Income tax expense (benefits) | 357 | 1,839 | 1,558 |
| Net profit (loss) of ongoing business for the current period | -157,094 | -698,344 | -915,208 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -157,094 | -698,344 | -915,208 |
| Other comprehensive profit (loss), net | -13,080 | -92,762 | 46,118 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -170,174 | -791,106 | -869,090 |
| Net profit (loss) attributable to owners of parent company | -157,094 | -698,344 | -915,208 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | -170,174 | -791,106 | -869,090 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 0 | -2 | -3 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | -111,754 | -311,443 | -848,556 |
| Net cash inflows (outflows) from investing activities | -71,031 | -1,015,048 | -219,018 |
| Net cash inflow (outflow) from financing activities | -123,172 | 370,890 | -6,820 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 1,164 | 2 | 692 |
| Increase (decrease) in cash and cash equivalents in the current period | -304,793 | -955,599 | -1,073,702 |
| Beginning balance of cash and cash equivalents | 4,097,584 | 5,053,183 | 6,126,885 |
| Ending balance of cash and cash equivalents | 3,792,791 | 4,097,584 | 5,053,183 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 5,227,534 | 5,952,002 | 6,915,506 |
| Non-current asset | 5,540,324 | 4,924,414 | 4,247,053 |
| Total asset | 10,767,858 | 10,876,416 | 11,162,559 |
| Current liability | 702,755 | 947,370 | 707,165 |
| Non-current liability | 1,214,328 | 670,789 | 437,931 |
| Total liability | 1,917,083 | 1,618,159 | 1,145,096 |
| share capital | 3,063,381 | 3,062,492 | 3,060,516 |
| Equity - secruity token | - | - | - |
| capital reserve | 6,959,252 | 6,954,889 | 7,830,216 |
| retained earning | -855,438 | -698,344 | -915,208 |
| Other equity | -10,955 | 230 | 41,939 |
| Treasury stock | -305,465 | -61,010 | - |
| Total equity attributable to owners of parent company | 8,850,775 | 9,258,257 | 10,017,463 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 8,850,775 | 9,258,257 | 10,017,463 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 122,000 | 33,000 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 4,000,000 | 841,000 | 0 |
| Net asset value per share | 29 | 30 | 32 |
| 標案名稱 | 機關名稱 | 決標日期 | 決標金額 | 是否得標 |
|---|---|---|---|---|
| 飛確新型冠狀病毒抗原快速檢驗試劑壹批 | 國立成功大學 | 110/07/20 | 840000.0 | 是 |
| COVID-19抗原快速檢測試劑緊急採購案 | 臺中市政府衛生局 | 110/07/02 | 1850000.0 | 是 |
| 新型新冠病毒抗原快速檢驗試劑採購案 | 新北市政府衛生局 | 110/05/26 | 4500000.0 | 是 |
| 110年度新型冠狀病毒快速檢測試劑 | 屏東縣檢驗中心 | 110/05/20 | 1864800.0 | 是 |
| 候選疫苗之產程開發與先導製程最適化委託服務-細胞庫生產及特性驗證分析 | 財團法人國家衛生研究院 | 109/07/29 | 4500000.0 | 是 |
| 人類IL12p80蛋白質(人類IL12p40同二聚體) | 財團法人國家衛生研究院 | 106/07/04 | 1370000.0 | 是 |
